Research

Serum Interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study

Kathleen D Liu¹, Christopher Altmann², Gerard Smits², Catherine D Krawczeski³, Charles L Edelstein², Prasad Devarajan⁴ and Sarah Faubel²

¹Divisions of Nephrology and Critical Care Medicine, Departments of Medicine and Anesthesia, University of California, San Francisco, San Francisco, CA, USA
²Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, University of Colorado Denver, Aurora, CO, USA
³Section of Cardiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA
⁴Section of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA

Corresponding author: Sarah Faubel, Sarah.faubel@ucdenver.edu

Received: 6 Mar 2009 Revisions requested: 23 Apr 2009 Revisions received: 22 May 2009 Accepted: 1 Jul 2009 Published: 1 Jul 2009

Critical Care 2009, 13:R104 (doi:10.1186/cc7940)

Abstract

Introduction Acute kidney injury (AKI) is associated with high mortality rates. New biomarkers that can identify subjects with early AKI (before the increase in serum creatinine) are needed to facilitate appropriate treatment. The purpose of this study was to test the role of serum cytokines as biomarkers for AKI and prolonged mechanical ventilation.

Methods This was a case-control study of children undergoing cardiac surgery. AKI was defined as a 50% increase in serum creatinine from baseline within 3 days. Levels of serum interleukin (IL)-1β, IL-5, IL-6, IL-8, IL-17, interferon (IFN)-γ, tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured using a bead-based multiplex cytokine kit in conjunction with flow-based protein detection and the Luminex LabMAP multiplex system in 18 cases and 21 controls. Levels of IL-6 and IL-8 were confirmed with single-analyte ELISA; IL-18 was also measured with single-analyte ELISA.

Results IL-6 levels at 2 and 12 hours after cardiopulmonary bypass (CPB) and IL-8 levels at 2, 12 and 24 hours were associated with the development of AKI using the Wilcoxon rank-sum test and after adjustment for age, gender, race, and prior cardiac surgery in multivariate logistic regression analysis. In patients with AKI, IL-6 levels at 2 hours had excellent predictive value for prolonged mechanical ventilation (defined as mechanical ventilation for more than 24 hours postoperatively) by receiver operator curve (ROC) analysis, with an area under the ROC curve of 0.95. IL-8 levels at 2 hours had excellent predictive value for prolonged mechanical ventilation in all patients. Serum IL-18 levels were not different between those with and without AKI.

Conclusions Serum IL-6 and IL-8 values identify AKI early in patients undergoing CPB surgery. Furthermore, among patients with AKI, high IL-6 levels are associated with prolonged mechanical ventilation, suggesting that circulating cytokines in patients with AKI may have deleterious effects on other organs, including the lungs.

Introduction

Acute kidney injury (AKI) in hospitalized patients is associated with unacceptably high mortality rates (in the range of 30% to 50% in most recent series for dialysis-requiring AKI) [1,2]. In addition, the costs associated with AKI are high, as AKI translates into longer lengths of stay as well as a frequent need for invasive procedures (e.g., line placement and dialysis).

At present, therapies for AKI are limited to supportive care, such as dialysis. A number of major impediments exist to developing therapies for AKI. First, biomarkers that diagnose
AKI before an increase in serum creatinine are needed (reviewed in [3,4]). Because serum creatinine is a marker of glomerular filtration rate and therefore of established AKI, substantial kidney injury may have occurred by the time serum creatinine increases. Second, the pathogenesis of AKI in humans is complex and involves the endothelial and epithelial cell compartments, as well as inflammatory cells. Finally, AKI may have a detrimental impact on other organs, particularly the lung [5-7]. Predicting distant organ injury is critical to developing better therapies for AKI, because other end-organ injury may be a major mechanism for morbidity and mortality related to AKI.

AKI is associated with inflammation. In patients with established AKI, serum interleukin (IL-6, IL-8, IL-1β, IL-10 and tumor necrosis factor-α (TNF-α), were increased [8]. In an animal model of AKI, we demonstrated that inflammatory cytokines increase early after AKI as serum interleukin-6 (IL-6) and keratinocyte-derived cytokine (KC, the murine analogue of interleukin-8) were increased by 2 hours after AKI [9]. Whether these and other cytokines might be early biomarkers of AKI in patients, and whether these biomarkers would predict other adverse outcomes in patients with AKI are unknown. To test whether serum cytokines might be early biomarkers of AKI, we examined serum IL-1β, IL-5, IL-6, IL-8, IL-10, IL-17, IL-18, interferon (IFN)-γ, TNF-α, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) in pediatric patients with and without AKI, 2, 12, and 24 hours after cardiopulmonary bypass (CPB). Based on our animal data, we hypothesized that IL-6 and IL-8 would be early biomarkers of acute kidney injury.

In animals, we and others demonstrated that AKI causes lung injury, characterized by neutrophil infiltration and increased capillary permeability [6,9-14]. Furthermore, we recently demonstrated that IL-6 mediates lung injury after both ischemic AKI and bilateral nephrectomy, and that this effect may be dependent on KC (the murine analogue of IL-8) [15]. Therefore, we also hypothesized that early biomarkers of AKI (e.g., IL-6 and IL-8) would predict the need for prolonged mechanical ventilation in this study.

Materials and methods

Study subjects

All children undergoing correction of congenital heart disease at Cincinnati Children’s Hospital between January 2004 and November 2004 were eligible. Exclusion criteria included pre-existing renal insufficiency, diabetes mellitus, peripheral vascular disease, and use of nephrotoxic drugs before or during the study period. Written informed consent was obtained from the legal guardian of each child; the study was approved by the Cincinnati Children’s Hospital Institutional Review Board. This study population was previously described in detail [16,17]. As part of standard management, children were treated with a one-time dose of 30 mg/kg methylprednisolone on the CPB pump, with a maximum dose of 500 mg. All of the children received modified ultrafiltration per protocol at the end of surgery. All study subjects received intravenous fluids per a standard protocol (80% of maintenance fluids on postoperative day 1 and 100% of maintenance fluids on subsequent postoperative days). None of the patients had oliguria. Weaning from mechanical ventilation and extubation occurred per protocol.

Study procedures

Serum creatinine was measured at baseline and at least twice a day postoperatively and at least daily after postoperative day 3. Blood samples were collected at baseline and at 2, 12, and 24 hours after the initiation of CPB, and then once daily for 5 days. When the CPB time was less than 2 hours, the first postoperative serum samples were obtained at the end of CPB, and this sample was considered the 2-hour sample. The primary outcome variable was development of AKI, defined as a 50% or greater increase in serum creatinine from baseline within 3 days. Other variables obtained included age, sex, ethnic origin, CPB time, previous heart surgery, urine output, and duration of mechanical ventilation.

Statistical analysis

Baseline characteristics and cytokine levels of subjects who did and did not develop acute kidney injury were compared. Categoric variables were expressed as proportions and compared by using the χ² test. Continuous variables were expressed as mean ± standard deviation or median with interquartile range and were compared by using Student’s t test or the Wilcoxon rank-sum test, where appropriate.

We next examined the association between biomarker measurements (predictor) and acute kidney injury or prolonged mechanical ventilation (outcomes), by using multivariable logistic regression to adjust for other covariates. Biomarker levels were log transformed because these were not normally distributed. We adjusted for age, sex, race, andoperative characteristics. Model discrimination was assessed using ROC curves [18]. Model fit (calibration) was assessed using the Hosmer-Lemeshow goodness-of-fit test, which compares model performance (observed vs. expected) across deciles of risk. A nonsignificant value for the Hosmer-Lemeshow χ² suggests an absence of biased fit. Data analysis was conducted by using Stata 10 (StataCorp, College Station, TX, USA). A P value of less than 0.20 was considered potentially significant for interaction. In other cases, two-tailed P values less than 0.05 were considered significant.

Flow cytometry and enzyme-linked immunoassay (ELISA) determination for serum cytokines

Serum IL-1β, IL-5, IL-6, IL-8, IL-10, IL-17, IFN-γ, TNF-α, G-CSF, and GM-CSF were measured in duplicate using a bead-based multiplex cytokine kit (Bio-Rad, Hercules, CA, USA) in conjunction with flow-based protein detection and the Luminex LabMAP multiplex system (Luminex, Austin, TX, USA)
according to the manufacturers’ directions. The detection limit for each cytokine was 1.95 pg/ml. To confirm results obtained with the multiplex cytokine array, serum IL-6 and IL-8 were measured in duplicate by the appropriate single ELISA (R&D Systems, Minneapolis, MN, USA). The lower limit of detection for IL-6 is less than 0.7 pg/ml, and the detection limit for IL-8 is 1.5 to 7.5 pg/ml. Serum IL-18 was measured in duplicate by single ELISA (Medical and Biologic Laboratories, Nagoya, Japan); the detection limit for IL-18 is 25 pg/ml.

**Results**

**Patient characteristics**

This was a nested case-control study of a cohort of children undergoing CPB for correction of congenital heart disease. The cohort of patients was previously described and consists of patients with clear ischemic acute kidney injury due to CPB [16,17]. In brief, 100 consecutive children undergoing CPB surgery were considered for study; 29 were excluded for nephrotoxin use. Acute kidney injury (AKI) was defined by a 50% or greater increase in serum creatinine within a 3-day postoperative period. Of the 71 eligible study subjects, AKI developed in 20 patients. Eighteen of the AKI subjects had sufficient serum remaining for analysis of cytokines; 21 controls were selected from the patients without AKI.

No differences were found between subjects in whom AKI developed and those in whom it did not with regard to age, sex, ethnicity, or baseline creatinine (Table 1). AKI was associated with longer CPB times ($P = 0.0005$). A strong association was noted between AKI and the need for prolonged mechanical ventilation, defined as ventilation for more than 24 hours after CPB.

In bivariate analysis, IL-6 and IL-8 levels at 2 and 12 hours were independently associated with the development of acute kidney injury (Table 2). After adjustment for age, sex, race, and whether the patient had previous surgery, IL-6 levels at 2 hours and IL-8 levels at 2 and 12 hours remained predictive for AKI. Because prolonged CPB time is a known risk factor for AKI, postoperative hours ($P = 0.009$). Cardiac surgical procedures in children with and without AKI are detailed in Additional data file # 1.

**Serum cytokine levels and AKI**

Serum IL-1β, IL-5, IL-6, IL-8, IL-10, IL-17, IFN-γ, TNF-α, G-CSF, and GM-CSF were measured at baseline (before CPB) and at 2, 12, and 24 hours after CPB with a multiplex protein-detection method. Compared with AKI-free controls, patients with AKI had significantly increased serum IL-6 and IL-8 levels. No significant differences were observed for IL-1β, IL-5, IL-10, IL-17, IFN-γ, TNF-α, G-CSF, or GM-CSF at any time point (data not shown). Serum IL-18, as measured with ELISA, was also not different between patients with versus those without AKI.

As shown in Figure 1, levels of IL-6 and IL-8 by single-analyte ELISA were not different at the time of CPB between children in whom AKI developed and those in whom it did not. IL-6 and IL-8 levels peaked in both groups at 2 hours after CPB. IL-6 levels were significantly higher in children with AKI at 2 and 12 hours, compared with those without AKI. IL-8 levels were significantly higher in children with AKI at 2, 12, and 24 hours after CPB.

![Figure 1](http://ccforum.com/content/13/4/R104)

Table 1

| Baseline characteristics of patients with and without acute kidney injury |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | No acute kidney injury      | Acute kidney injury         | $P$ value                   |
| Number                      | 21                          | 18                          |                             |
| Age (years)*                | 2.1 ± 2                     | 3 ± 5.2                     | 0.46                        |
| Male (%)                    | 62%                         | 50%                         | 0.46                        |
| White (%)                   | 86%                         | 83%                         | 0.84                        |
| Redo surgery                | 24%                         | 39%                         | 0.31                        |
| CPB time (minutes)*         | 87 ± 44                     | 136 ± 63                    | 0.007                       |
| Baseline Cr (mg/dl)*        | 0.4 ± 0.08                  | 0.4 ± 0.17                  | 0.92                        |
| Peak Cr (mg/dl)*            | 0.4 ± 0.11                  | 0.9 ± 0.58                  | 0.0007                      |
| CVP (mm Hg)*‡               | 10.6 ± 2.6                  | 10.6 ± 3.4                  | 0.99                        |
| Mechanical ventilation at 24 h (%)| 33%                         | 78%                         | 0.006                       |
| Hospital length of stay (days)†| 4 [3,6]                     | 10.5 [8,30]                 | <0.0001                     |
| Death (%)                   | 0                           | 11%                         | 0.12                        |

*Mean ± SD
† Median [25, 75% interquartile range].
‡ Measured 2 hours after CPB.
and because we hypothesized that high inflammatory cytokine levels are the result of AKI, we specifically chose not to adjust for CPB time in our multivariable model. Alternatively, one of the pathogenetic mechanisms for AKI after CPB is through inflammatory processes mediated by IL-6 and IL-8; thus, cytokine levels and CPB time would not be expected to have independent predictive value in a model for AKI. Similarly, because IL-6 and IL-8 likely represent a common inflammatory pathway, we did not adjust for both cytokines in the same predictive model. Last, we examined the performance of various cut points in cytokine levels for the diagnosis of AKI (Table 3).

**Figure 1**

![Graphs showing serum IL-6 and IL-8 levels over time](image)

Serum IL-6 and IL-8 are increased in patients with acute kidney injury (AKI) following cardiopulmonary bypass (CPB). (a) Serum IL-6 was determined at 0, 2, 12, and 24 hours after cardiopulmonary bypass, and median levels were significantly increased 2 and 12 hours after CPB in patients with AKI versus patients without AKI. *P < 0.01; **P < 0.05. (b) Serum IL-8 was determined at 0, 2, 12, and 24 hours after cardiopulmonary bypass, and median levels were significantly increased at 2, 12, and 24 hours in patients with AKI versus patients without AKI. *P < 0.05; **P < 0.001.

**Table 2**

| Cytokine       | Odds ratio | 95% CI      | P value | Odds ratio* | 95% CI      | P value |
|----------------|------------|-------------|---------|-------------|-------------|---------|
| IL-6 at 2 hours | 3.56       | 1.26–9.90   | 0.02    | 3.47        | 1.21–9.97   | 0.02    |
| IL-6 at 12 hours | 3.17      | 1.04–9.66   | 0.04    | 3.29        | 0.86–12.64  | 0.08    |
| IL-6 at 24 hours | 1.45       | 0.67–3.15   | 0.34    | 1.48        | 0.57–3.80   | 0.42    |
| IL-8 at 2 hours | 2.87       | 1.25–6.55   | 0.01    | 4.98        | 1.39–17.86  | 0.01    |
| IL-8 at 12 hours | 4.37      | 1.40–13.64  | 0.01    | 9.74        | 1.75–54.20  | 0.009   |
| IL-8 at 24 hours | 2.44       | 0.85–6.97   | 0.10    | 4.98        | 0.85–29.15  | 0.08    |

Logistic regression was used to determine the association between IL-6 and IL-8 levels at various times after cardiopulmonary bypass and the diagnosis of acute kidney injury. Because biomarker levels were abnormally distributed, they were log transformed, and odds ratios represent the increase in risk per log increase in biomarker level.

*Adjusted for age, sex, race, and previous surgery
When we analyzed the association between cytokine levels and the requirement for prolonged mechanical ventilation, an interaction between IL-6 levels and acute kidney injury was detected ($P = 0.06$). An interaction was not detected between IL-8 levels and acute kidney injury ($P = 0.83$). We therefore stratified the analysis of IL-6 levels by the presence or absence of AKI. IL-6 levels were associated with prolonged mechanical ventilation only in study subjects with acute kidney injury ($P = 0.008$ vs $P = 0.9$ in those without AKI). Indeed, IL-6 levels at 2 hours had excellent predictive value for prolonged mechanical ventilation in patients with AKI, with an area under the ROC curve of 0.95 (Figure 3). IL-8 levels at 2 hours had excellent predictive value for prolonged mechanical ventilation in all patients, with an area under the ROC curve of 0.89 (Figure 4).

**Discussion**

In the present study, we have demonstrated that, in children undergoing CPB, AKI is characterized by high levels of serum IL-6 and IL-8. IL-6 and IL-8 levels at 2 and 12 hours after CPB were predictive for subsequent AKI. Furthermore, among children with AKI, early increases in serum IL-6 are predictive of prolonged mechanical ventilation.

We previously demonstrated in animal models that early AKI (i.e., within 2 hours of the original insult) is a proinflammatory state. Whereas other studies have demonstrated that increased serum IL-6 predicts subsequent AKI [19,20], these studies were conducted in critically ill patients with severe sepsis and acute lung injury. In those studies, the timing of the underlying AKI insult was less clear because of the underlying severity of illness of study subjects. IL-6 was elevated between 1 and 7 days before the detection of AKI, so the timing of the IL-6 elevation relative to AKI was also less clear. Thus, AKI may have contributed to high levels of IL-6, or may have been the result of the patient’s proinflammatory state.

In our study, patients were children undergoing CPB, in which the major insult is the surgery and bypass itself. Thus, the timing of the insult is clear. Based on our animal studies, we hypothesized that levels of proinflammatory cytokines would increase early after the ischemic insult (e.g., CPB). Indeed, levels of IL-6 and IL-8 were elevated 2 hours after CPB in patients with AKI, well before a detectable increase in creatinine. These results are similar to those observed with other urine and plasma biomarkers of AKI that have been measured in this cohort, including urinary IL-18, serum/urinary neutrophil-gelatinase-associated lipocalin (NGAL), urinary kidney injury mole-

| Performance of serum IL-6 and IL-8 for the diagnosis of acute kidney injury at various times after cardiopulmonary bypass |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **IL-6 at 2 hours**                              | **Sensitivity (%)** | **Specificity (%)** | **Positive predictive value (%)** | **Negative predictive value (%)** | **Area under the ROC curve** |
| ≥175 pg/ml                                      | 44               | 85               | 63               | 73               |
| ≥125 pg/ml                                      | 78               | 80               | 69               | 87               |
| ≥75 pg/ml                                       | 83               | 25               | 39               | 73               |

| **IL-8 at 2 hours**                              | **Sensitivity (%)** | **Specificity (%)** | **Positive predictive value (%)** | **Negative predictive value (%)** | **Area under the ROC curve** |
| ≥100 pg/ml                                      | 44               | 80               | 56               | 72               |
| ≥70 pg/ml                                       | 67               | 65               | 52               | 78               |
| ≥40 pg/ml                                       | 83               | 45               | 46               | 83               |

| **IL-8 at 12 hours**                             | **Sensitivity (%)** | **Specificity (%)** | **Positive predictive value (%)** | **Negative predictive value (%)** | **Area under the ROC curve** |
| ≥100 pg/ml                                      | 18               | 100              | 100              | 68               |
| ≥70 pg/ml                                       | 35               | 100              | 100              | 73               |
| ≥40 pg/ml                                       | 71               | 74               | 60               | 82               |

*Because positive and negative predictive values will vary based on AKI prevalence, we assumed a prevalence of 36%, as in [17].
cule-1 (KIM-1), and urinary liver fatty acid-binding protein (L-FABP) [16,17,21,22].

Although CPB is associated with an increase in proinflammatory cytokines [23], data are accumulating that AKI may affect both the production and clearance of cytokines. For example, in animal models of ischemic AKI, increased renal production of both IL-6 and KC (the murine analogue of IL-8) have been documented [9,24,25]. Increased serum cytokines also are detected after bilateral nephrectomy [9], a model of renal failure in which both kidneys are removed, and therefore, the kidney cannot be a source of increased serum cytokines in this model. Thus, extrarenal production of cytokines or impaired clearance of cytokines may also occur in acute renal failure and contribute to elevated serum levels. In this regard, pharmacokinetic studies in animals demonstrated that the kidney plays a key role in the clearance of cytokines [26-28]. In patients, a negative correlation has been demonstrated between serum IL-6 levels and glomerular filtration rate [29], further implicating the kidney in cytokine clearance. Available evidence suggests that cytokines are cleared by the kidney predominantly through filtration, resorption, and metabolism by the proximal tubule [30], although filtration and excretion of the intact protein can occur [9]. In our study, concomitant AKI resulted in a greater than threefold increase in serum IL-6 and IL-8 2 hours after CPB versus CPB alone. Thus, although serum cytokines increase after CPB itself, the increase is much greater in the presence of AKI and may be due to decreased clearance or increased production or both.

Mechanical ventilation is a consistent, independent predictor of mortality in patients with AKI [31-35], and a recent study demonstrated that patients with AKI required mechanical ventilation for more days than did patients with similar severity of illness who did not have AKI [36]. The reasons for the prolonged duration of mechanical ventilation in patients with AKI is unknown. In mice, IL-6 signalling effects are increased in the lung after AKI [37], and our recently published data demonstrate that IL-6 mediates lung injury after AKI, as IL-6-deficient and IL-6 antibody-treated mice had reduced lung inflammation, capillary leak, and serum and lung KC after AKI [15].
These results to other populations is unclear. However, given
made up of children undergoing CPB, so the generalizability of
systemic cytokines. The study population is relatively small and
other end organs in human disease through its effects on sys-
tematic target.

Although the role of IL-6 in other forms of lung injury has not
been examined, a pathogenic role of IL-6 in ventilator-associ-
ated lung injury has been hypothesized [38]; patients receiving
lung-protective ventilation (6 ml/kg tidal volume) had lower
serum IL-6 levels, which predicted reduced mortality and more
ventilator-free days versus patients receiving standard ventila-
tion (12 ml/kg tidal volume) [39]. In the present study, we dem-
strate that in patients with AKI, increased serum IL-6 2
hours after CPB was predictive for prolonged mechanical ven-
tilation. Recognizing that we are unable to prove causality in
this context, we hypothesize that AKI directly contributes to
prolonged mechanical ventilation, perhaps through higher lev-
els of IL-6 leading to increased inflammation and lung injury.
Thus, IL-6 may be both a diagnostic marker of AKI and pro-
longed mechanical ventilation, as well as a potential therapeu-
tic target.

Our study has several strengths. As stated previously, our
study subjects were children undergoing CPB surgery. There-
fore, the timing of the increase in IL-6 and IL-8 levels relative to
the ischemic insult is clear and, as in our animal models,
occur early after injury. Furthermore, this is a well-character-
ized cohort of children, in whom other plasma and urine
biomarkers of AKI have been shown to have excellent predic-
tive value. Our study also has some limitations. Because this is
a clinical study, our results are associations and cannot prove
causality. However, our results are similar to our prior observa-
tions in animal models [9] and suggest that AKI may affect
other end organs in human disease through its effects on sys-
temic cytokines. The study population is relatively small and
made up of children undergoing CPB, so the generalizability of
these results to other populations is unclear. However, given
their lack of other comorbidities, this pediatric population has
been invaluable for studies of ischemic AKI unconfounded by
other diseases that could contribute to a proinflammatory state
(e.g., sepsis). Further studies in critically ill adult populations
are warranted to confirm and extend our findings; however,
these studies are likely to be confounded by the contribution
of other disease states to systemic cytokine levels.

Conclusions
We have shown that serum IL-6 and IL-8 levels increase early
after CPB and are predictive of AKI in a pediatric population.
Based on data from animal models in which AKI itself leads to
elevated IL-6 and IL-8 levels, we hypothesize that the increase
in IL-6 and IL-8 is because of increased cytokine generation or
reduced cytokine clearance in the setting of AKI. Furthermore,
among patients with AKI, IL-6 levels are predictive of pro-
longed mechanical ventilation. This result is similar to our prior
results in animal models, in which AKI resulted in higher serum
IL-6 levels and concomitant lung injury. Thus, serum cytokines
may have an important role as early biomarkers for AKI, as well
as a potential role as a therapeutic target in AKI. Modulation of
these cytokines may reduce the degree of kidney injury itself,
as well as the deleterious effects of kidney injury on other end
organs, including the lung.

Key messages
- The proinflammatory cytokines IL-6 and IL-8 are
increased early (at 2 hours) in patients with AKI due to
CPB.
- Other serum cytokines, including IL-18, are not
increased in patients with AKI.
- Among patients with AKI, serum IL-6 predicts pro-
longed mechanical ventilation.
- Serum IL-6 and IL-8 may be useful early biomarkers to
detect AKI and predict complications (i.e., prolonged
mechanical ventilation).

Competing interests
KDL, CA, GS, CDK and SF have no competing interests to
disclose. CE holds US Patent 7,141,382 for IL-18 as an early
biomarker of AKI. PD is on the Advisory Board of Abbott Diag-
nostics and Biosite, Inc., and has licensing agreements with
Abbott and Biosite for developing NGAL as a biomarker for
acute renal failure.

Authors’ contributions
KDL performed the statistical analysis and drafted the manu-
script. CA carried out biomarker measurements. GS per-
formed the initial statistical analysis. CE was responsible for
the serum IL-18 analyses and participated in the design of the
study. CDK was responsible for recruiting the patients, obtain-
ing the samples, and maintaining the clinical database. PD
designed and carried out the original cohort study of children
undergoing CPB and participated in the design of this study. SF conceived of the study, participated in its design and coordination, performed biomarker measurements, and drafted the manuscript. All authors read and approved the final manuscript.

Additional files

The following Additional files are available online:

**Additional file 1**

The following additional data are available with the online version of this article. Additional data file 1 is a table listing the cardiac surgical procedures performed in children in this cohort. See http://www.biomedcentral.com/content/ supplementary/cc7940-S1.doc

Acknowledgements

The study was supported by the following research grants: American Heart Association, Beginning Grant in Aid (07600752) and American Society of Nephrology Gottschalk Award to SF, NIH/NCRR/OD UCSF-Heart Association, Beginning Grant in Aid (0760075Z) and American

References

1. Hoste EA, Schunior M: Epidemiology of acute kidney injury: how big is the problem? *Crit Care Med* 2008, 36:S146-S151.
2. Lameire N, Van Biesen W, Vanholder R: Acute renal failure. *Lancet* 2005, 365:417-430.
3. Zhou H, Hewitt SM, Yuen PS, Star RA: Acute kidney injury biomarkers - needs, present status, and future promise. *Nephrol Self Assess Program*. 2006, 5:83-71.
4. Waikar SS, Bonventre JV: Biomarkers for the diagnosis of acute kidney injury. *Curr Opin Nephrol Hypertens* 2007, 16:557-564.
5. Rabb H, Chamoun F, Hotchkiss J: Molecular mechanisms underlying combined kidney-lung dysfunction during acute renal failure. *Contrib Nephrol* 2001, 132:41-52.
6. Deng J, Hu X, Yuen PS, Star RA: Alpha-melanocyte-stimulating hormone inhibits lung injury after renal ischemia/reperfusion. *Am J Physiol Renal Physiol* 2004, 287:F749-756.
7. Faubel S: Pulmonary complications after acute kidney injury. *Adv Chronic Kidney Dis* 2008, 15:284-296.
8. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Pagani EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikoler TA: Plasma cytokine levels predict mortality in patients with acute renal failure. *Kidney Int* 2004, 65:1357-1365.
9. Hoke TS, Douglas IS, Klein CL, He Z, Fang W, Thuman JM, Tao Y, Dursun B, Voelkel NF, Edelstein CL, Faubel S: Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. *J Am Soc Nephrol* 2004, 15:1815-1814.
10. Kramer AA, Postler G, Salhab KF, Mendez C, Carey LC, Rabb H: Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. *Kidney Int* 1999, 55:2362-2367.
11. Burns-Taney M, Koffer J, Yokota N, Weisfeldt M, Tratman R, Rabb H: Acute renal failure after whole body ischemia is characterized by inflammation and T-cell mediated injury. *Am J Physiol Renal Physiol* 2003, 285:F87-F94.
12. Kim do J, Park SH, Sheen MR, Jeon US, Kim SW, Koh ES, Woo SK: Comparison of experimental lung injury from acute kidney failure with injury due to sepsis. *Respiration* 2006, 73:815-824.
13. Nath KA, Grande JP, Croatt AJ, Frank E, Caplice NM, Hebbl RP, Katusic ZS: Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. *Am J Pathol* 2005, 166:963-972.
14. Hassoun HT, Grigoryev DN, Lie ML, Liu M, Ceddie C, Tuder RM, Rabb H: Ischemic acute kidney injury induces a distant organ functional and genomic response distinguishable from bilateral nephrectomy. *Am J Physiol Renal Physiol* 2007, 293:F30-F40.
15. Klein CL, Hoke TS, Fang WF, Altman CJ, Douglas IS, Faubel S: Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. *Kidney Int* 2008, 74:901-909.
16. Mishra J, Dent C, Tarabishi R, Mitsnefes M, Ma Q, Kelly C, Ruff S, Zahedi K, Zhao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 2005, 365:1231-1234.
17. Klein CL, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL: Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 2006, 70:199-203.
18. Hanley J, McNeil B: The meaning and use of the area under the receiver operating characteristic (ROC) curve. *Radiology* 1982, 143:29-36.
19. Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL: Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. *Clin J Am Soc Nephrol* 2007, 2:22-30.
20. Liu KD, Glidden DV, Eisner MD, Parsons PE, Ware LB, Wheeler A, Korpak A, Thompson BT, Chertow GM, Matthay MA: Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. *Crit Care Med* 2007, 35:2755-2761.
21. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P: Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 2008, 74:465-472.
22. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV: Urinary biomarkers in the early diagnosis of acute kidney injury. *Kidney Int* 2008, 73:863-869.
23. Butler J, Rosker GM, Westaby S: Inflammatory response to cardiopulmonary bypass. *Ann Thorac Surg* 1993, 55:552-559.
24. Kieler ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquest B, Nagami GT, Lu CY: Maladaptive role of IL-6 in ischemic acute kidney injury. *J Am Soc Nephrol* 2005, 16:3315-3325.
25. Nechemia-Arleny Y, Barkan D, Pizov G, Shiri A, Rose-John S, Galun E, Axelrod JH: IL-6/IL-6R axis plays a critical role in acute kidney injury. *J Am Soc Nephrol* 2008, 19:1106-1115.
26. Rachmawati H, Belijaars L, Reker-Smit C, Van Loenen-Weemaes AM, Hagensen WI, Meijer DK, Poelstra KC: Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. *Pharm Res* 2004, 21:2072-2078.
27. Benelmans MH, van Tols L, Buurman WA: Tumor necrosis factor: function, release and clearance. *Crit Rev Immunol* 1996, 16:111.
28. Bocci V: Interleukins: clinical pharmacokinetics and practical implications. *Clin Pharmacokinet* 1991, 21:274-284.
29. Pecotis-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-E sparse AM, Hagens WI, Meijer DK, Poelstra KC: Pharmacokinetic and distribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. *Pharm Res* 2004, 21:2072-2078.
30. Benelmans MH, van Tols L, Buurman WA: Tumor necrosis factor: function, release and clearance. *Crit Rev Immunol* 1996, 16:111.
replacement therapy on outcome in critically ill patients. *Crit Care Med* 2002, 30:2051-2058.

34. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: *Acute renal failure in critically ill patients: a multinational, multicenter study*. *JAMA* 2005, 294:813-818.

35. Wakar SS, Liu KD, Chertow GM: *The incidence and prognostic significance of acute kidney injury*. *Curr Opin Nephrol Hypertens* 2007, 16:227-236.

36. Vieira JM Jr, Castro I, Curvello-Neto A, Demarzo S, Caruso P, Pastore L Jr, Imanishe MH, Abdulkader RC, Deheinzelin D: *Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients*. *Crit Care Med* 2007, 35:184-191.

37. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H: *The local and systemic inflammatory transcriptome after acute kidney injury*. *J Am Soc Nephrol* 2008, 19:547-558.

38. Puneet P, Moochhala S, Bhatia M: *Chemokines in acute respiratory distress syndrome*. *Am J Physiol Lung Cell Mol Physiol* 2005, 288:L3-L15.

39. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP: *Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*. *Crit Care Med* 2005, 33:1-6. discussion 230-232.